Axentis Pharma is a respiratory specialty pharmaceutical company which core competence is the application of a fully patented, encapsulating drug delivery system to already established and well-characterized therapeutic agents. Currently, the company is using this technology, named Fluidosomes™ technology, for the development of its lead product, a clinical stage treatment against cystic fibrosis (CF).

Fluidosomes™ tobramycin or ARB-CF0223 is a fully patented, inhalable liposomal formulation of tobramycin, delivered directly to the site of infection via standard nebulizers. Fluidosomes™ tobramycin has an improved safety profile and higher efficacy compared to current treatments for infections of the respiratory tract in patients with cystic fibrosis.

The Fluidosomes™ technology provides means to site-specific delivery of aerosolized drugs, and, hence, offers a huge potential to innovatively address other chronic lung diseases besides cystic fibrosis. Two additional indications are currently being investigated for in-vitro proof of concept.